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Background: The independent functions of the glycerol-3-phosphate acyltransferase (GPAT) isoforms are unknown.
Results:When comparedwithGpat4/,Gpat1/ hepatocytes oxidizedmore fatty acids (FA) andwere unable to incorporate
de novo synthesized FA into triacylglycerol.
Conclusion: GPAT1, but not GPAT4, metabolizes FA synthesized de novo from [14C]acetate and diverts FA away from mito-
chondrial oxidation.
Significance: GPAT1 and GPAT4 use different cellular pools of FA.
Four glycerol-3-phosphate acyltransferase (GPAT) isoforms,
each encoded by a separate gene, catalyze the initial step in glyc-
erolipid synthesis; in liver, the major isoforms are GPAT1 and
GPAT4. To determine whether each of these hepatic isoforms
performs a unique function in the metabolism of fatty acid, we
measured the incorporation of de novo synthesized fatty acid or
exogenous fatty acid into complex lipids in primary mouse
hepatocytes from control, Gpat1/, and Gpat4/ mice.
Although hepatocytes from each genotype incorporated a simi-
lar amount of exogenous fatty acid into triacylglycerol (TAG),
only control andGpat4/hepatocyteswere able to incorporate
de novo synthesized fatty acid into TAG. When compared with
controls, Gpat1/ hepatocytes oxidized twice as much exoge-
nous fatty acid. To confirm these findings and to assess hepatic
-oxidation metabolites, we measured acylcarnitines in liver
frommice after a 24-h fast and after a 24-h fast followed by 48 h
of refeeding with a high sucrose diet to promote lipogenesis.
Confirming the in vitro findings, the hepatic content of long-
chain acylcarnitine in fasted Gpat1/ mice was 3-fold higher
than in controls. When compared with control and Gpat4/
mice, after the fasting-refeeding protocol, Gpat1/ hepatic
TAG was depleted, and long-chain acylcarnitine content was
3.5-fold higher. Taken together, these data demonstrate that
GPAT1, but not GPAT4, is required to incorporate de novo syn-
thesized fatty acids into TAG and to divert them away from
oxidation.
Glycerol-3-phosphate acyltransferase (GPAT3; EC 2.3.1.15)
initiates the pathway of TAG synthesis by esterifying a long-
chain fatty acyl-CoA to a glycerol-3-phosphate backbone at the
sn-1 position to form sn-1-acylglycerol-3-phosphate (lysophos-
phatidic acid) (1). A second esterification at the sn-2 position is
catalyzed by acylglycerol-3-phosphate acyltransferase. The
phosphate is then hydrolyzed by phosphatidic acid phosphohy-
drolase (lipin), and then a final acylation is catalyzed by diacyl-
glycerol acyltransferase to form TAG. In addition to their roles
in TAG synthesis, the phosphatidic acid and diacylglycerol
intermediates in this pathway are precursors for all the glycero-
phospholipids, and they initiate signaling pathways.
The pathway ofTAGbiosynthesis is remarkable for the num-
ber of isoenzymes that catalyze each step. For example, four
independent GPAT isoforms, each encoded by a separate gene,
catalyze the formation of lysophosphatidic acid, but it is unclear
why GPAT enzyme redundancy is required. Studies of mice
with deleted GPATs show that the isoforms present in liver
include primarily GPAT1 (2) and GPAT4 (3, 4), with lower
expression of GPAT2 (5) and GPAT3 (6). Each of the GPAT
isoforms is an intrinsic membrane protein whose active site
faces the cytosol (7). GPAT1, located on the outer mitochon-
drialmembrane and at contact siteswith the endoplasmic retic-
ulum (8), has a strong preference for saturated fatty acids (1).
GPAT1 comprises 30–50% of total activity in liver (1), and
Gpat1mRNA expression is highly responsive to SREBP1c and
is up-regulated when dietary carbohydrate intake and circulat-
ing insulin concentrations are high (9). AbsentGPAT1 protects
against the development of hepatic steatosis caused by a high fat
diet (2) or by the up-regulation of SREBP1c in ob/obmice (10).
Conversely, GPAT1 overexpression causes hepatic steatosis
(11) and insulin resistance (12). GPAT4, which is located on the
endoplasmic reticulum and on lipid droplets (13), contributes
40–50% of total hepatic GPAT activity (3). Like GPAT1,
GPAT4 also appears to be important for hepatic TAG synthesis
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because the TAG content in Gpat4/ liver is 42% lower than
in control mice (3).
Hepatic triacylglycerol synthesis is enhanced by the
increased availability of long-chain fatty acids synthesized
within hepatocytes from dietary glucose or from fatty acid that
enters hepatocytes exogenously fromdietary chylomicron rem-
nants or as free fatty acids lipolyzed from adipose tissue.
Because SREBP1c concomitantly up-regulates both GPAT1
and the enzymes that catalyze the de novo synthesis of fatty
acids, including acetyl-CoA carboxylase and fatty acid synthase
(14), we hypothesized that the function of GPAT1 and de novo
lipogenesis might be intrinsically linked. To test this hypothe-
sis, we compared the ability of GPAT1 andGPAT4 to use exog-
enous versus de novo synthesized fatty acids in control and
knock-out mice and in their hepatocytes.
EXPERIMENTAL PROCEDURES
Materials—Type I collagenase was from Worthington Bio-
chemical Corp. [1-14C]Acetic acid and [1-14C]palmitic acid
were purchased from PerkinElmer Life Sciences. Silica G gel
plateswere fromWhatman. Tissue culture plateswere fromBD
Biosciences, and media were obtained from Invitrogen. Sigma
was the source of 4-methylene-2-octyl-5-oxotetrahydrofuran-
3-carboxylic acid (C75) and all other chemicals, unless other-
wise indicated.
Animal Care and Hepatocyte Isolation—Animal protocols
were approved by the University of North Carolina at Chapel
Hill Institutional Animal Care and Use Committee. Mice were
housed in a pathogen-free barrier facility on a 12-h light/dark
cycle with free access to water and food (Prolab 5P76 Isopro
3000; 5.4% fat by weight). Gpat1/ (2) and Gpat4/ (3, 15)
mice had been backcrossed at least eight times onto a C57BL6/J
background. At 8 weeks of age, littermate controls and
Gpat1/ and Gpat4/ mice were either fasted for 24 h or
fasted for 24 h and then refed a high sucrose diet for 48 h before
sacrifice. The high sucrose diet was modified from Research
Diets D12450B (10% kcal of fat, 20% kcal of protein, and 70%
kcal of carbohydrate (525 g/kg of sucrose, 175 g/kg of corn
starch)).
To isolate hepatocytes, aftermicewere anesthetizedwith 250
mg/kg of Avertin, a 22-gauge catheter was inserted into the
vena cava, and the liver was perfused with wash buffer (10 mM
Hepes, 132 mM NaCl, 6.7 mM KCl, 20 mM glucose, 0.5 M aden-
osine, 100 mM EGTA, 140 nM insulin, pH 7.4) and then with
digestion buffer (100 mM HEPES, 57 mM NaCl, 6.7 mM KCl, 5
mM CaCl2, 20 mM glucose, 0.45 mg/ml type 1 collagenase, pH
7.4). The digested liver was removed and placed in a 100-mm
dish on ice with Hanks’/BSA buffer (10 mM HEPES, 137 mM
NaCl, 5.4 mM KCl, 1.26 mM CaCl2, 0.8 mM MgSO4, 4.2 mM
NaHCO3, 0.34 mMNa2HPO4, 0.44 mMKH2PO4, 5 mM glucose,
pH 7.4). The hepatocytes were dissociated and filtered through
a cell strainer, centrifuged at 4 °C at 50  g for 3 min, and then
washed once in Williams’ medium E. The cells were resus-
pended in Williams’ medium E:Percoll (16 ml:14 ml), centri-
fuged at 4 °C at 400  g for 8 min, and washed with Williams’
medium E. Cells were plated onto 60-mm collagen-coated
dishes and incubated for 90 min inWilliams’ medium E  10%
FBS. After the cells attached, the medium was changed toWil-
liams’ medium E, 100 units of penicillin/streptomycin, 50 nM
insulin, 0.1 M dexamethasone, and 0.1% BSA.
GPAT Activity—Hepatocytes were cultured overnight in
60-mm plates and then scraped and homogenized in cold
Medium I (250mM sucrose, 10 mMTris, pH 7.4, 1 mM EDTA, 1
mM dithiothreitol) with 10 up-and-down strokes with a Teflon
glass motor-driven homogenizer. Liver was minced and then
homogenized similarly. Totalmembranes were isolated by cen-
trifuging the homogenate at 100,000  g for 1 h. GPAT specific
activitywas assayed for 10min at room temperature in a 200-l
reaction mixture containing 75 mM Tris-HCl, pH 7.5, 4 mM
MgCl2, 1 mg/ml BSA (essentially fatty acid-free), 1 mM dithio-
threitol, 8 mM NaF, 800 M [3H]glycerol 3-phosphate, and 80
M palmitoyl-CoA (20). The reaction was initiated by adding
10–30g ofmembrane protein after incubating themembrane
protein on ice for 15 min in the presence or absence of 2 mM
N-ethylmaleimide (NEM), which inactivates GPAT isoforms 2,
3, and 4. The reaction products were extracted into CHCl3,
dried under N2, resuspended in 4 ml of Cytoscint, and counted
on a scintillation counter. NEM-resistant activity (GPAT1) was
calculated by subtracting NEM-sensitive activity from total
activity.
RNA Extraction and RT-PCR—Total RNA was extracted
from overnight cultures of hepatocytes with TRIzol (Invitro-
gen). cDNA synthesis and real time RT-PCRwere performed as
described (3). Primer sequences for each GPAT isoform and
data normalization used were described (3, 32).
Labeling, Oxidation, and Lipid Extraction—Sixteen to 20 h
after plating, hepatocytes were labeled with 0.5 ml of labeling
buffer (Krebs Ringer buffer, 10mMHEPES, 5.5mM glucose, 0.25%
fatty acid-free bovine serum albumin (BSA), and 1 mM carnitine)
containing 500M [1-14C]acetic acid or [1-14C]palmitic acid for
2 h.Media were removed, and CO2 was liberated by adding 100
l of 70% perchloric acid and trapped in 1 M NaOH. An aliquot
of the NaOH was counted to measure radiolabeled CO2. To
quantify intracellular oxidationmetabolites, fresh Krebs Ringer
buffer and 100 l of 70% perchloric acid were added to each
plate, and acidified supernatants were collected. The acidified
media and cell supernatants were incubated overnight with
BSA and then centrifuged at 14,000  g for 20 min. Aliquots of
the supernatant were counted to measure radiolabeled acid-
soluble metabolites (ASM), a measure of incomplete fatty acid
oxidation. Cells were washed with 1% BSA and then with phos-
phate-buffered saline before lipids were extracted (16). Lipid
extracts and standards were separated by thin layer chroma-
tography on Partisil LK5D silica gel plates in a two-phase
system: chloroform:methanol:ammonium hydroxide (65:
25:4, v/v/v) run to 50% of the plate and then dried and fol-
lowed by heptane:isopropyl ether:acetic acid (60:40:4, v/v/v)
run to the top of the plate. Radiolabeled lipids were quanti-
fied with a Bioscan AR-2000 imaging scanner. Lipid stand-
ards were visualized by iodine staining.
Blood Chemistries and Lipids—Before blood collection, mice
were either fasted for 24 h or fasted 24 h and then fed a high
sucrose diet for 48 h. Plasma TAG (Stanbio, Boerne, TX), free
fatty acid (WakoDiagnostics, Richmond, VA), glucose (glucose
CII reagent,WakoDiagnostics), and-hydroxybutyrate (Wako
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Diagnostics) were determined by enzymatic colorimetric
methods.
Lipid Extraction and TAGMeasurement in Liver—Liver lip-
ids were extracted (12), dried under N2 gas, resuspended in 200
l of tert-butanol:methanol:Triton X-100 (3:1:1, v/v), and ana-
lyzed colorimetrically as described above.
Liver Acylcarnitine Measurement—Livers were snap-frozen
in liquid nitrogen, pulverized, and weighed. The pulverized
liver (50–100 mg) was homogenized in acetonitrile:water:for-
mic acid (50:49.7:0.3; v/v) at a final concentration of 50 mg/ml.
Acylcarnitines were analyzed by flow injection tandem mass
spectrometry (17). Samples were stored at 80 °C before
analysis.
Statistics—Data representmeans S.E. of at least three inde-
pendent experiments performed in triplicate unless indicated
otherwise. In vitromodels were analyzed by one-way analysis of
variance comparing each genotype versus controls and post hoc
comparisons of diet conditions within each genotype. Data
were considered significant at p  0.05.
RESULTS
Isolated and Cultured Primary Hepatocytes Retained GPAT
Specific Activity—To compare the contributions of GPAT1 and
GPAT4 to the total amount of GPAT activity, we isolated
and cultured primary hepatocytes from control,Gpat1/, and
Gpat4/ mice and measured GPAT specific activity in the
presence and absence of NEM, which inhibits GPAT2, 3, and 4
(Fig. 1A). When compared with wild type hepatocytes, total
GPAT specific activity inGpat1/ hepatocytes was 35% lower
and minimal residual NEM-resistant GPAT activity remained,
whereas NEM-sensitive GPAT activity was unchanged. Total
GPAT specific activity inGpat4/ hepatocytes was 42% lower
than in control hepatocytes; NEM-resistant GPAT specific
activity was unchanged, but NEM-sensitive GPAT activity was
60% lower. The residual NEM-sensitive GPAT activity is likely
due to GPAT2 and -3. These results show that isolated and
cultured primary hepatocytes retained GPAT activity and that
the specific activity was similar in Gpat1/ and Gpat4/
hepatocytes.
To determine whether other GPAT isoforms were affected
by deletion of either GPAT1 or GPAT4, we measured mRNA
expression of each GPAT isoform (Fig. 1B). InGpat1/ hepa-
tocytes, Gpat3 mRNA abundance was 2-fold higher than in
wild type hepatocytes, but NEM-sensitive GPAT activity did
not change, indicating a lack of compensation. In the absence of
GPAT4, the mRNA expression of Gpat2 and -3 increased 2.5-
and 3.5-fold, respectively. GPAT2 activity is extremely low in
liver (5), and evenwhen the amount ofGpat2mRNAdoubles, it
probably does not contribute substantially to total NEM-sensi-
tive GPAT activity. However, because we cannot differentiate
between GPAT3 and GPAT4 protein or activity, the 42% lower
NEM-sensitive GPAT activity (Fig. 1B) could reflect partial
compensation by GPAT3.
The Incorporation of de Novo Synthesized Fatty Acid into
TAG Required GPAT1—Because GPAT1 is up-regulated by
SREBP1c, we hypothesized that it might be functionally and
specifically linked to de novo lipogenesis, such that newly syn-
thesized fatty acids would be incorporated into TAG. Using
[1-14C]acetate, we measured the ability of control, Gpat1/,
and Gpat4/ hepatocytes to incorporate de novo synthesized
fatty acid into TAG and PL. The incorporation of acetate into
TAG and PL was equal in hepatocytes from wild type and
Gpat4/ mice; however, in Gpat1/ hepatocytes, the incor-
poration of [14C]acetate into PLwas 78% lower than in controls,
and the incorporation into TAG was virtually absent (Fig. 2, A
and B). When wild type and Gpat4/ hepatocytes were cul-
tured in the presence of the fatty acid synthase inhibitor C75,
[14C]acetate incorporation into TAG was inhibited 80–85%
(Fig. 2A). However, inGpat1/ hepatocytes, C75 had no addi-
tional effect, indicating that the absence of GPAT1 in hepato-
cytes had abolished the incorporation of the de novo synthe-
sized fatty acid. In wild type and Gpat4/ hepatocytes, C75
decreased acetate incorporation into PL by 60%, but only by
27% in Gpat1/ hepatocytes (Fig. 2B). In each group of hepa-
tocytes, the addition of C75 decreased the incorporation of ace-
tate into free fatty acids by more than 72% (data not shown).
These results show that GPAT1, but not GPAT4, is required to
incorporate de novo synthesized fatty acid into complex lipids.
Both GPAT1 and GPAT4 Can Incorporate Exogenous Fatty
Acids into TAG and Phospholipid—In addition to de novo syn-
thesis, liver fatty acids are also derived from exogenous sources.
FIGURE 1. GPAT specific activity and mRNA expression in primary hepatocytes from wild type, Gpat1/, and Gpat4/ mice. A, GPAT specific activity
was measured in total particulate preparations of primary hepatocytes cultured for 16 h; results show triplicates from two independent experiments. Total,
N-ethylmaleimide-resistant (NEM-R), and N-ethylmaleimide-sensitive (NEM-S) GPAT specific activities are shown. B, mRNA expression of each GPAT isoform was
measured by RT-PCR. Total RNA was obtained from primary hepatocytes in triplicate from two experiments. Data are presented as means  S.E.
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To distinguish between the functions of GPAT1 and GPAT4 in
the use of exogenous fatty acids, we measured the incorpora-
tion of [1-14C]palmitate into glycerolipids in primary hepato-
cytes. In contrast to fatty acids derived from de novo synthesis,
the incorporation of [1-14C]palmitate into TAG and PLwas not
altered by the absence of eitherGPAT1 orGPAT4 (Fig. 3,A and
B), indicating that neither isoform was essential for the use of
exogenous fatty acid. Thus, in both Gpat4/ and Gpat1/
hepatocytes, the remaining GPAT isoforms can fully incorpo-
rate exogenous fatty acid into glycerolipids.
In Hepatocytes, the Absence of GPAT1, but Not GPAT4,
Increased Fatty Acid Oxidation—Previous studies have
strongly suggested that GPAT1 competes with CPT1 for acyl-
CoAs at the outer mitochondrial membrane (12). To confirm
this competition for acyl-CoAs and to determine whether
GPAT4 located on the endoplasmic reticulum competes simi-
larly, we measured the incorporation of [1-14C]palmitate into
ASM, a measure of incomplete fatty acid oxidation. Gpat1/
hepatocytes oxidized [14C]palmitate at a rate 200% higher than
control hepatocytes, but the incorporation of [14C]palmitate
into ASM by Gpat4/ hepatocytes was unchanged (Fig. 3C).
Of the total ASM extracted from the media and cells, intracel-
lular ASM comprises only 5% of the total ASM (Fig. 3C, inset);
thus, media ASM reflect 95% of the total ASMproduced. These
data show that only GPAT1 competes with CPT1 for acyl-
CoAs, thereby diminishing the flux of fatty acid into the mito-
chondria for oxidation.
Hepatic GPAT1 Diminished Fatty Acid Transport into Mito-
chondria in Vivo—To confirm the disparate effects of each
GPAT isoform on the -oxidation of exogenous versus de novo
synthesized fatty acid in vivo, we measured hepatic acylcarni-
tine content in wild type, Gpat1/, and Gpat4/ mice after
food was removed for 24 h. Because fasting increases the flux of
adipose-derived fatty acids into the liver, more fatty acids are
transported to the mitochondria via CPT1, thereby elevating
the content of hepatic long-chain acylcarnitines. These metab-
olites are subsequently reconverted to acyl-CoAs in the mito-
chondrial matrix, where they enter the-oxidation pathway. In
fasting mice of each genotype, the content of free carnitine
(C0), acetylcarnitine (C2), and short-chain (C3-C6) and medi-
um-chain (C8-C12) acylcarnitine species was similar (Fig. 4, A
and C). Consistent with the hypothesized ability of GPAT1 to
compete with CPT1 for acyl-CoAs, total long-chain (C14-C22)
acylcarnitine content in fastedGpat1/ liverwas 3-fold higher
than in control liver (Fig. 4C). The most abundant long-chain
acylcarnitine species, 14:0, 16:1, 16:0, 18:2, 18:1, and 18:0, were
2–6-fold higher than in control liver (Fig. 4E). In contrast, and
consistent with the in vitro data, the acylcarnitine content in
livers of fasted Gpat4/ mice was similar to that of control
mice.
Because GPAT1 was essential for the incorporation of de
novo synthesized fatty acids into complex lipids in vitro, we
predicted that the absence of hepatic GPAT1 in vivowould also
increase the transport of de novo synthesized fatty acids into
mitochondria. To test this hypothesis, we fasted mice for 24 h
and then refed them with a high sucrose diet for 48 h to stimu-
late de novo lipogenesis. The total long-chain (C14-C22) acyl-
carnitine content of Gpat1/ liver remained 3.5-fold higher
than that of controls, and the most abundant long-chain acyl-
carnitine species, 14:0, 16:1, 16:0, 18:2, 18:1 and 18:0, ranged
from 2- to 5-fold higher (Fig. 4,D and F). In contrast, no differ-
ences were observed in the hepatic acylcarnitine content of
Gpat4/mice that had been fasted and then refed (Fig. 4,B,D,
and F). Thus, GPAT1, but not GPAT4, was required in vivo to
diminishCPT1-mediated transport of bothde novo synthesized
and exogenous fatty acid.
Hepatic GPAT1 Was Essential for the Incorporation of de
Novo Synthesized Fatty Acid into TAG—Because the absence of
GPAT1 increased hepatic -oxidation of de novo synthesized
fatty acids in vivo, we predicted that the liver TAG content
would be low. After a 24-h fast, hepatic TAGcontent in control,
Gpat4/, and Gpat1/ liver was similar. After refeeding a
high sucrose diet to enhance de novo lipogenesis, the TAG con-
tent in control and Gpat4/ liver increased 2–2.5-fold (Fig.
5A); however, the hepatic TAG content of Gpat1/ liver did
not increase. These data support the conclusion that GPAT1 is
essential for the incorporation of de novo synthesized fatty acid
into TAG and for diverting those fatty acids away from mito-
chondrial oxidation.
The Absence of GPAT1, but Not GPAT4, Increased Ketogen-
esis during Fasting—When the concentration of plasma glucose
decreases during an extended fast, adipocyte-derived fatty acids
flood into the liver, their oxidation rate increases, and ketone
bodies are synthesized and secreted into the blood. The accu-
FIGURE 2. Gpat1/ hepatocytes incorporated less [14C]acetate into glycerolipids. Hepatocytes were labeled with 500 M [1-14C]acetate in the presence
or absence of 20 g/ml C75 for 2 h. A and B, [1-14C]acetate incorporation into triacylglycerol (A) or phospholipids (B) in control, Gpat1/, or Gpat4/
hepatocytes. Data show means  S.E. of two experiments performed in triplicate.
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mulation of long-chain acylcarnitines in the liver together with
an elevated plasma concentration of ketone bodies suggests an
increased rate of hepatic fatty acid oxidation. Because GPAT1
diminishes the oxidation of exogenous fatty acid in vitro and the
absence of GPAT1 in liver results in the accumulation acylcar-
nitines, we predicted that fastingwould result in a higher rate of
hepatic -oxidation in Gpat1/ mice than in controls. To
confirm this hypothesis, we measured plasma ketone bodies in
control, Gpat1/, and Gpat4/ mice. After a 24-h fast, the
concentrations of plasma glucose and TAG in control and
Gpat1/ mice were similar (Fig. 5, B and C), but the plasma
fatty acid concentration in Gpat1/ mice was 1.5-fold higher
than controls (Fig. 5D). Consistent with elevated fatty acid oxi-
dation in the Gpat1/ mice, the plasma concentration of
-hydroxybutyrate was 2-fold higher than controls (Fig. 5E).
Ketogenesis Remained Elevated in Gpat1/ Mice during
Refeeding—After a 24-h fast, refeeding with high sucrose drives
hepatic de novo lipogenesis, promotes TAG storage, and blocks
fatty acid oxidation (18). Because our data suggested that
GPAT1 esterifies de novo synthesized fatty acids, we asked
whether the rate of hepatic fatty acid oxidation would remain
elevated during short-term high sucrose refeeding. Although a
high carbohydrate diet diminishes PPAR gene targets related
to -oxidation and ketone body formation, in the absence of
GPAT1, the plasma -hydroxybutyrate concentration in
Gpat1/ mice was 3-fold higher than in control or Gpat4/
mice (Fig. 5D), consistent with a continued higher rate of
hepatic fatty acid oxidation. Consistent with diminished
hepatic TAG synthesis in both Gpat1 and Gpat4 null mice,
when compared with controls, the plasma TAG concentration
was 48% lower in Gpat1/ mice and 25% lower in Gpat4/
mice (Fig. 5C). Plasma glucose and fatty acid concentrations in
each genotype were similar (Fig. 5, B and E).
DISCUSSION
With the discovery of four independent GPAT isoforms that
differ in tissue distribution, subcellular location, acyl-CoApref-
erence, and transcriptional regulation, questions have arisen as
to the specific function of each isoform (1). Gpat2 mRNA is
most strongly expressed in testes and probably plays a minor
role in liver, but the mRNA expression and activities in liver of
the remaining GPAT isoforms are high (1, 5, 6, 19). Although
studies suggest that GPAT3 is regulated by PPAR and PPAR
in keratinocytes (20) and by insulin-mediated phosphorylation
in 3T3-L1 adipocytes (21), the regulation and specific contribu-
tions of hepatic GPAT3 to glycerolipid synthesis are unknown.
The availability of Gpat1 and Gpat4 knock-out mice, however,
has allowed us to directly compare them and to delineate the
specific roles of each isoform.
The function of GPAT1 in the esterification of fatty acids has
been best studied. GPAT1 esterification rates for 16:0-CoA are
3–10 times higher than those observed with 18:0-, 18:1-,
18:2n6-, and 18:3n3-CoAs (21–24). Examination of the glycer-
FIGURE 3. GPAT1 was not required for the incorporation of exogenous fatty acid, and -oxidation was higher in Gpat1/ hepatocytes. Hepatocytes
from wild type, Gpat1/ (G1/), or Gpat4/ (G4/) mice were labeled with 500 M [1-14C]palmitic acid for 2 h. A–C, [1-14C]palmitic acid incorporation into
triacylglycerol (A), phospholipids (B), and ASM (C). Data show means  S.E. of two experiments performed in triplicate. Inset, comparison of cell media and
intracellular (IntraC) ASM. Data show means of one experiment performed in quadruplicate.
FIGURE 4. Long-chain acylcarnitine content was higher in Gpat1/ liver
than controls after a 24-h fast and after 48 h of refeeding. Wild type,
Gpat1/, and Gpat4/ mice were fasted for 24 h or fasted for 24 h and then
refed with a high sucrose diet for 48 h. A and B, hepatic content of free carni-
tine (C0) and acetylcarnitine (C2). C and D, short-, medium-, and long-chain
acylcarnitine content of mouse liver. E and F, major hepatic long-chain acyl-
carnitine species from mice. Data are shown as means  S.E. Significant dif-
ferences are indicated by * for genotype. (p  0.05, analysis of variance) (n 
6 diet, genotype).
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olipid species inGpat1/ liver have confirmed the preference
of GPAT1 for 16:0-CoA because the absence of GPAT1 results
in decreases in the amounts of 16:0 esterified to phosphatidyl-
choline and phosphatidylethanolamine in membranes from
total liver (2) and from liver mitochondria (25). The 16:0 defi-
ciencies at the sn-1 position of phosphatidylcholine and phos-
phatidylethanolamine are compensated by increases in the
content of 18:1 at the sn-1 position and of 20:46 at the sn-2
position.
A second function ofGPAT1 is related tode novo lipogenesis.
This role is implied by the fact that the specific activity of
GPAT1 is low in liver during fasting, in part because of inhibi-
tion by AMP-activated kinase (26), and is up-regulated tran-
scriptionally when lipogenesis from carbohydrate precursors is
enhanced. Similar to acyl-CoA carboxylase and fatty acid syn-
thase, Gpat1 mRNA, protein, and specific activity increase in
response to SREBP1c up-regulation, which, in turn, is stimu-
lated by insulin and depressed via liver X receptor by polyun-
saturated fatty acids (9). Thus, GPAT1 is markedly elevated in
ob/obmice, and a deficiency in ob/obmice of eitherGpat1 itself
(10) or of SREBP1c (14) protects against the development of a
fatty liver. In addition to promoting the synthesis of TAG, indi-
rect evidence suggests that GPAT1 diverts acyl-CoAs away
from CPT1 and -oxidation because long-chain acylcarnitines
and -hydroxybutyrate increase in Gpat1/ mice fed an obe-
sogenic diet that is high in sucrose and palm oil (12). Thus,
under conditions when the synthesis of fatty acid is elevated,
the presence of GPAT1 would ensure that the resulting fatty
acids are esterified rather than oxidized. Our current data
directly support this idea.
In isolated hepatocytes, incubationwith [14C]acetate showed
that only the deficiency of GPAT1 blocked the incorporation of
de novo synthesized fatty acids into glycerolipids. The incorpo-
rationwas equivalent in control andGpat4/ hepatocytes and
was diminished equally by the fatty acid synthase inhibitor C75.
These data suggest that fatty acids synthesized de novo from
glucose require GPAT1 to be incorporated into TAG. Perhaps
because of the preference ofGPAT1 for 16:0-CoA, the predom-
inant species synthesizedde novoby fatty acid synthase,GPAT1
was also responsible for most of the acetate-derived fatty acid
that was incorporated into PL. Inhibition of fatty acid synthesis
by C75 had a weaker effect on PL synthesis than it did on TAG
synthesis, suggesting that de novo synthesized fatty acids may
be preferentially directed to TAG storage, consistent with the
fact that lipogenesis is up-regulated when high carbohydrate
intake and insulin concentrations activate SREBP1c. The final
step in the synthesis of TAG is catalyzed by DGAT1 and
DGAT2. Stable isotope studies show that only DGAT2 incor-
porates fatty acids synthesized de novo (27).
Because Gpat1/ hepatocytes failed to incorporate label
from [14C]acetate into TAG, we concluded that GPAT1 is
required for the synthesis of TAG from de novo lipogenesis.
Confirming this interpretation, after the fasting-refeeding pro-
tocol to promote hepatic de novo lipogenesis, Gpat1/ liver
contained 53% less TAG than did controls. When compared
with fastedmice, the hepatic TAGcontent in both refed control
and refedGpat4/ mice increased 2- and 3-fold, respectively,
but liver TAG content in refed Gpat1/ mice did not change,
indicating thatGpat1/ failed to incorporate de novo-derived
fatty acid into hepatic TAG. A direct comparison of hepatic
-oxidation revealed that when compared with controls, long-
chain acylcarnitines and -hydroxybutyrate in Gpat1/ mice
were 3.5- and 2-fold higher, respectively. Thus, when hepatic
GPAT1 was absent, the de novo synthesized fatty acids were
oxidized rather than incorporated into TAG. These data are
consistent with our in vitro findings and confirm that GPAT1 is
required to incorporate de novo synthesized fatty acids into
TAG and diminish fatty acid oxidation.
In humans, VLDL secretion is stimulated by dietary sugars,
and after a high carbohydrate load, de novo synthesized fatty
acids comprise roughly 37% of plasma VLDL-TAG (28, 29).
Consistent with a role for GPAT1 in incorporating de novo
synthesized fatty acids into VLDL, Gpat1/ mice fed a diet
containing 60% of calories from sucrose were protected from
hypertriglyceridemia and showed diminished VLDL secretion
rates (30). After the fasting-refeeding protocol, plasma TAG
FIGURE 5. Liver and plasma metabolites. A, liver TAG content of wild type, Gpat1/, and Gpat4/ mice fasted for 24 h or fasted for 24 h and then refed with
a high sucrose diet for 48 h. B, plasma glucose; C, plasma TAG; D, plasma fatty acid; E, plasma -hydroxybutyrate. Data are shown as means  S.E. Significant
differences are indicated by * for genotype and by # for diet challenge. (p  0.05, analysis of variance) (n  6 diet, genotype).
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concentrations in Gpat1/ mice did not change, suggesting
that GPAT1 is essential for the postprandial lipemia that is
stimulated by carbohydrate feeding. In contrast, plasma TAG
in refed control and Gpat4/ mice increased 2- and 3.5-fold,
respectively, consistent with the continued presence and func-
tion of GPAT1 in using de novo synthesized TAG in VLDL.
The absence of either GPAT1 or GPAT4 did not block the
incorporation of exogenous fatty acid into TAG or PL. Normal
incorporation seems surprising because TAG content in both
Gpat1/ and Gpat4/ liver is 40–50% lower than controls
(2, 31). However, our hepatocyte studies measured TAG syn-
thesis from [14C]palmitate in the absence of insulin. Normally,
after a 24-h fast, when insulin levels are low, fatty acids released
from adipocytes constitute the majority of the fatty acid enter-
ing the liver to be stored or incorporated into VLDL-TAG, a
process that is not sensitive to plasma insulin levels (28). Under
these conditions, fatty acids entering the liver might be prefer-
entially oxidized for energy, and the remaining low GPAT
activity would suffice for a minimal demand for TAG synthesis
for storage or for VLDL secretion. Consistent with this idea and
with our in vitro results, liver TAG content was similar in fast-
ing control, Gpat1/, and Gpat4/ mice. After feeding in
humans, concomitant with a rise in plasma insulin, both dietary
fatty acids and those derived from de novo synthesis are incor-
porated into TAG (28). Because the TAG content inGpat1/
liverwas lower than in controls after high sucrose refeeding, it is
likely that insulin-induced SREBP1c activity drove fatty acid
flux toward TAG storage; however, in the absence of GPAT1,
the remaining GPAT activity was unable to meet the demand
for higher TAG synthesis.
BecauseGpat1/mice fed lowor high fat diets for 4months
had a higher content of plasma and liver acylcarnitines and
higher concentrations of plasma -hydroxybutyrate, we had
speculated that GPAT1 might normally divert fatty acids away
from CPT1 and -oxidation (12). The present results directly
support this hypothesis by showing that when compared with
controls,Gpat1/ hepatocytes produced twice as much ASM
from [14C]palmitate and that plasma -hydroxybutyrate and
hepatic acylcarnitines were markedly elevated in Gpat1/
mice under both fasted and refed conditions. In contrast, ASM
production was similar in Gpat4/ and control hepatocytes
under both conditions, indicating that lack of GPAT4 did not
increase the use of excess acyl-CoAs for -oxidation.
To directly compare -oxidation metabolites from the two
Gpat null genotypes, we investigated acylcarnitines. After a
24-h fast, the hepatic content of long-chain acylcarnitines was
equivalent in control and Gpat4/ mice. Confirming the
hypothesis that GPAT1 competes with CPT1 for acyl-CoAs
and diverts them away frommitochondria, the content of long-
chain acylcarnitines in Gpat1/ livers was 3-fold higher than
controls. Thus, despite the observation that exogenous fatty
acid incorporation into TAG was unaffected by a deficiency of
either GPAT1 or GPAT4, these results further support the
unique function of GPAT1 in diverting fatty acids away from
-oxidation.
These studies clearly differentiate the roles of the major
hepatic isoforms, GPAT1 and GPAT4. GPAT1, but not
GPAT4, reciprocally regulates hepatic de novo glycerolipid syn-
thesis and fatty acid oxidation. In this role, the absence of
GPAT1 protects mice from high fat diet- and genetic-induced
hepatic steatosis and hepatic insulin resistance (10). Con-
versely, the increased expression of GPAT1 may contribute to
insulin resistance, both by diverting fatty acids away from oxi-
dation and toward glycerolipid synthesis and by increasing lipid
intermediates such as diacylglycerol and phosphatidic acid,
which impair hepatic insulin signaling (11, 32).
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